A district court in India ruled against Novartis AG, which had argued a key element of India's 2005 patent law violated World Trade Organization rules, freeing Indian generics makers to continue making less expensive versions of drugs. The case had stemmed from a suit over a patent for a new version of the Novartis leukemia drug Gleevec. The drugmaker said it wasn't likely to appeal the decision, but said it could have a negative impact on drug R&D.

Related Summaries